Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.59 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.58 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20832 | 0.95 | ALDH1A1 (0.60) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL9878722 | 0.91 | ALDH1A1 (0.56) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL8362713 | 0.88 | HPGD (0.53) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL5697654 | 0.86 | HPGD (0.51) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL635657 | 0.86 | ALDH1A1 (0.51) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL10777357 | 0.85 | HPGD (0.50) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL31110325 | 0.85 | HPGD (0.47) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL10599027 | 0.85 | HPGD (0.50) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL3355910 | 0.85 | HPGD (0.50) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL29044412 | 0.85 | ALDH1A1 (0.67) | HPGDALDH1A1ALOX12BRCA1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890382-B2 | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230176038-A1 | Methods for Identifying Modulators of Insect Transient Receptor Potential Channels | BASF CORP (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230149316-A1 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2021133566-A1 | METHODS FOR IDENTIFYING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3311172-B1 | METHODS FOR IDENTIFYING COMPOUNDS THAT DIRECTLY BIND TO INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3087391-B1 | METHODS FOR DETERMINING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL V (TRPV) CHANNEL | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3735982-A1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | The University of Massachusetts (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200246438-A1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | UNIV MASSACHUSETTS (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200188311-A1 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3268025-B1 | TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY | UNIV MASSACHUSETTS (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2003004604-A9 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH INC (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004003554-A1 | A METHOD FOR THE DETECTION OF APOPTOSIS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030235611-A1 | Direct cellular energy delivery system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-25 | — | — | US | disclosed |
| WO-2003096973-A2 | A DIRECT CELLULAR ENERGY DELIVERY SYSTEM | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097792-A2 | POLYPEPTIDE IMMOBILIZATION | THE UNIVERSITY OF CHICAGO (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086174-A2 | A NEW METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030194754-A1 | Method for the diagnosis and prognosis of malignant diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| US-20030148264-A1 | Phage displayed PDZ domain ligands | GENENTECH, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030119054-A1 | Polypeptide immobilization | NATIONAL SCIENCE FOUNDATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003004604-A2 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148264-A1 | Phage displayed PDZ domain ligands | PDLIM5, CD2BP2, GOPC | HPGD 4611/4885ALDH1A1 4481/4885ALOX12 4863/4885 |
| US-20030119054-A1 | Polypeptide immobilization | SURF4, QPCTL, QPCT | HPGD 4638/4885ALDH1A1 3904/4885ALOX12 3552/4885 |
| US-20030235611-A1 | Direct cellular energy delivery system | NSF, MTREX, SLC25A6 | HPGD 2380/4885ALDH1A1 3960/4885ALOX12 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.